Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 1012-1019

  Djalalov, Sandjar ^a,b   Beca, Jaclyn ^a,b   Hoch, Jeffrey S ^a,b   Krahn, Murray ^b,c   Tsao, Ming Sound ^d   Cutz, Jean Claude ^e   Leighl, Natasha B ^b,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Canadian Centre for Applied Research in Cancer Control (ARCC)   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; ERLOTINIB; GEMCITABINE; MICROTUBULE ASSOCIATED PROTEIN; PEMETREXED; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENE FUSION; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; CANCER STAGING; CHEMISTRY; COST BENEFIT ANALYSIS; ECONOMICS; GENE FREQUENCY; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; GENE FREQUENCY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; ONTARIO; PYRAZOLES; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84901191153     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.1186     Document Type: Article

References (33)

1. American Cancer Society: Cancer Facts and Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf
2. Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med 359:1367-1380, 2008
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
4. Dienstmann R, Martinez P, Felip E: Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2:165-177, 2011
5. Shaw AT, Kim DW, Nakagawa K, et al: Phase III study of crizotinib ves pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (profile 1007). Presented at the 37th European Society for Medical Oncology Congress, Vienna, Austria, September 28-October 2, 2012 (abstr 2862)
6. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
7. Kim DW, Ahn MJ, Shi Y, et al: Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 30:499s, 2012 (suppl; abstr 7533)
8. Crystal AS, Shaw AT: New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol 9:207-214, 2011
9. Takeuchi K, Choi YL, Togashi Y, et al: KIF5BALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143-3149, 2009
10. Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571, 2010
11. Paik JH, Choe G, Kim H, et al: Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol 6:466-472, 2011
12. McLeer-Florin A, Moro-Sibilot D, Melis A, et al: Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol 7:348-354, 2012
13. Yi ES, Boland JM, Maleszewski JJ, et al: Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6:459-465, 2011
14. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007 (Pubitemid 46174133)
15. Leighl NB: Treatment paradigms for patients with metastatic non-small-cell lung cancer: First-, second-, and third-line. Curr Oncol 19:S52-S58, 2012 (suppl 1)
16. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
17. Guidelines for the Economic Evaluation of Health Technologies: Canada (ed 3). Ottawa, Ontario, Canada, Canadian Agency for Drugs and Technologies in Health, 2006
18. Tsao MS, Craddock K, Brandao G, et al: Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements. J Clin Oncol 31, 2013 (suppl 15; abstr 8096)
19. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
20. Chen W: Cost-Effectiveness of Epidermal Growth Factor Receptor Gene Mutation Testing For Patients With Advanced Non-Small Cell Lung Cancer Living in Ontario. http://old-theta.phm.utoronto.ca/papers/theta-EGFR-testing-for-lung- cancer.pdf
21. Nafees B, Stafford M, Gavriel S, et al: Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6:84, 2008
22. Ontario Case Costing Initiative (OCCI). http://www.occp.com/mainPage.htm
23. Hon H, Qiu X, Tobros K, et al: Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). J Clin Oncol 30:383s, 2012 (suppl; abstr 6005)
24. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
25. Sacher AG, Le LW, Lau A, et al: Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents. J Clin Oncol 30:505s, 2012 (suppl; abstr 7606)
26. Atherly AJ, Camidge DR: The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 106:1100-1106, 2012
27. Canadian Cancer Society Steering Committee on Cancer Statistics: Canadian Cancer Statistics 2011. Toronto, Ontario, Canada, Canadian Cancer Society, 2011
28. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non- small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
29. Wong DW, Leung EL, So KK, et al: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723-1733, 2009
30. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
31. Janku F, Garrido-Laguna I, Petruzelka LB, et al: Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 6:1601-1612, 2011
32. Woolhandler S, Campbell T, Himmelstein DU: Costs of health care administration in the United States and Canada. N Engl J Med 349:768-775, 2003 (Pubitemid 37010782)
33. Sguires D: Explaining High Health Care Spending in the United States: An International Comparison of Supply, Utilization, Prices, and Quality. http://www.commonwealthfund.org/Publications/Issue-Briefs/2012/May/ High-Health-Care-Spending.aspx